Form 4: Atrium Therapeutics Director Reports Stock Transaction
Insider Transaction (Form 4)
W. Michael Flanagan, a Director of Atrium Therapeutics, Inc., reported a transaction in 22,812 shares of common stock on September 18, 2026.
Summary
- Tax/exercise-price withholding: disposed of 22,812 Common Stock at $8.95 ($204,167) on September 18, 2026; holds 31,974 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
W. Michael Flanagan — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-18 | Tax/exercise-price withholding | Common Stock | 22,812 | $9 | $204.2K | 31,974 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-18 | Tax/exercise-price withholding (22,812 shares) |
Keywords
insider transaction, Form 4, RNA, Atrium Therapeutics, Inc., neutral, W. Michael Flanagan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.